Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 62 results for neuropathic pain

  1. Head and neck cancer (QS146)

    This quality standard covers assessing, diagnosing and managing head and neck cancer, including cancer of the upper aerodigestive tract in people aged 16 and over. It describes high-quality care in priority areas for improvement.

  2. Spinal cord stimulator implantation: Improving theatre efficiency

    availability of beds and workforce challenges” (NHS Improvement 2019). NHS Pain Departments, along with other specialties, struggle for...

  3. Multiple sclerosis in adults: management (NG220)

    This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.

  4. Spinal metastases and metastatic spinal cord compression (NG234)

    This guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC). It is also relevant for direct malignant infiltration of the spine and associated cord compression. It aims to improve early diagnosis and treatment to prevent neurological injury and improve prognosis.

  5. Differential target multiplexed spinal cord stimulation for chronic lower back and leg pain (MIB305)

    NICE has developed a medtech innovation briefing (MIB) on differential target multiplexed spinal cord stimulation for chronic lower back and leg pain .

  6. Spotlight on valproate prescribing

    also used outside of its product licence (off-label use) for treating neuropathic pain, migraine, depression and dementia. If valproate...

  7. End of life care for infants, children and young people with life-limiting conditions: planning and management (NG61)

    This guideline covers the planning and management of end of life and palliative care for infants, children and young people (aged 0 to 17 years) with life-limiting conditions. It aims to involve children, young people and their families in decisions about their care, and improve the support that is available to them throughout their lives.

  8. Aptiva for painful diabetic neuropathy (MIB119)

    NICE has developed a medtech innovation briefing (MIB) on Aptiva for painful diabetic neuropathy .

  9. Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain (IPG739)

    Evidence-based recommendations on neurostimulation of lumbar muscles for refractory non-specific chronic low back pain in adults. This involves implanting a pulse generator under the skin of the upper buttock or lower back, which the person can use to manage their pain.

  10. Deep brain stimulation for refractory chronic pain syndromes (excluding headache) (IPG382)

    Evidence-based recommendations on deep brain stimulation for refractory chronic pain syndromes (excluding headache). This involves stimulating a precise area of the brain using an electrode to treat the chronic pain.

  11. Percutaneous image-guided cryoablation of peripheral neuroma for chronic pain (IPG747)

    Evidence-based recommendations on percutaneous image-guided cryoablation of peripheral neuroma for chronic pain. This involves using a needle-like probe to freeze and destroy small parts of nerves in neuromas to stop the pain signals.

  12. Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management (NG206)

    This guideline covers diagnosing and managing myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS) in children, young people and adults. It aims to improve awareness and understanding about ME/CFS and when to suspect it, so that people are diagnosed earlier. It includes recommendations on diagnosis, assessment and care planning, safeguarding, access to care and managing ME/CFS and its symptoms.

  13. Is response to pharmacological treatment predicted more reliably by underlying aetiology or by symptom characteristics?

    symptoms that present in healthcare settings, or whether different neuropathic pain conditions with different aetiologies, respond...

  14. Laparoscopic uterine nerve ablation (LUNA) for chronic pelvic pain (IPG234)

    Evidence-based recommendations on laparoscopic uterine nerve ablation (LUNA) for chronic pelvic pain. This involves the destruction of a small segment of ligament that carries nerve fibres within the pelvis.

  15. The Integrated Pain and Spinal Service (IPASS): A unique, integrated and collaborative approach to persistent pain management

    assessments and treatments for patients with back and generalised persistent pain. Using a holistic approach the team are able to...